View Older Stories View More Recent Stories
-
Roth Capital Starts The Joint Corp (JYNT) at Buy
-
Galena's (GALE) GALE-401 More Promising Following Presentation Phase 2 Data at ASH - Roth
-
Roth 'Encouraged' by Early Signs of BL-8040 Activity in AML; Affirms BioLineRx at 'Buy'
-
TG Therapeutics's (TGTX) TGR-1202 Keeps Getting Better; Roth Affirms 'Focus Pick' Rating
-
Roth Capital Starts Sky Solar (SKYS) at Buy
-
Roth Capital Downgrades LeapFrog (LF) to Neutral
-
Roth Comments on Celldex (CLDX) Following Initiation of CDX-011 Phase II
-
Roth Affirms Cytori (CYTX) at 'Buy'; Celution, ADRCs 'de-Risked' in Japan on New Regulatory Measures
-
Roth Capital Starts Renewable Energy Group (REGI) at Buy
-
Roth Capital Starts FutureFuel Corp. (FF) at Buy
-
Roth Capital Starts RSP Permian, Inc. (RSPP) at Buy
-
Roth Capital Starts Ring Energy, Inc. (REI) at Buy
-
Roth Capital Starts Clayton Williams Energy (CWEI) at Buy
-
Roth Capital Starts Callon Petroleum (CPE) at Buy
-
Regeneron's (REGN) Eylea sBLA Receives Priority Review as DME + Diabetic Retinopathy Treatment; Roth Capital Comments
-
TG Therapeutics (TGTX) Still 'Focus Pick' at Roth; New Phase 1/1b of TGR-1202 + Imbruvica Announced
-
Roth Affirms Can-Fite BioPharma (CANF) at 'Buy' Following Q3 Results; Still Sees FY15 as 'Breakout' Year
-
Roth Capital Starts Dynamic Materials (BOOM) at Buy
-
Revolution Lighting (RVLT) Prices 8M Common Offering at $1.25/Share
-
Trina Solar (TSL) Investors are Seeking More Visibility - Roth Capital
-
Revolution Lighting (RVLT) Announces Common Stock Offering
-
Streetinsider.com's Hot Lunchtime Reads 11/20: (LB) (AMZN) (REGN) (GS) (FB)
-
Regeneron's (REGN) Dupilumab Receives FDA Breakthrough Designation; Roth Capital Comments
-
Roth Updates Model on Trina Solar (TSL) Following Oct. Capital Raise; Affirms 'Buy' Rating
-
Roth Cuts PT on RGS Energy (RGSE) to 80c Following Q3 Miss, Lack of Guidance
-
Roth Comments on Regeneron (REGN) Following ODYSSEY Update at AHA (SNY)
-
Roth is Buyer of JA Solar (JASO) Following Q3 Results; Affirms 'Buy' Rating
-
Significant Partnership Could be in Store for Can-Fite (CANF) - Roth
-
Roth Capital Starts New Gold (NGD) at Neutral
-
Roth Capital Positive on Galena (GALE) Following Quick Enrollment of GALE-401 Phase 2
-
Roth Capital Comments on Keryx (KERX) Following KOL Panel; Affirms 'Buy' Rating
-
Notable Analyst Rating Changes 11/17: (MTG) (PSX) (CHK) Upgraded; (NOK) (ODP) (WTSL) Downgraded
-
Pre-Open Stock Movers 11/17: (CLDX) (BHI) (AGN) Higher; (DWA) (GSAT) (HAL) Lower (more...)
-
Roth Capital Lifts PT on Celldex (CLDX) to $43 Following Phase 2 ReACT Presentation
-
Roth Capital Downgrades Hecla Mining (HL) to Neutral
-
Roth Remains Positive on ImmunoCellular (IMUC) Following ICT-107 Phase 2 Presentation at SNO
-
Canadian Solar's (CSIQ) Margin Guidance Spooks Investors, Buy Industry Position Remains Strong - Roth
-
Roth Cuts PT on Plug Power (PLUG) to $4 Following 'Largely Disappointing' Q3 Report
-
Roth Trims Price Target on Concert (CNCE) to $21; CTP-354 Phase II Delayed on Toxicity Signal
-
Roth Capital Upgrades Dendreon (DNDN) to Neutral
-
Roth Comments on Galena (GALE) Following Initiation of Herceptin Combo Trial
-
Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
-
The Joint Corp (JYNT) IPO Opens Slightly Higher
-
Roth Affirms Sunesis (SNSS) at 'Neutral'; ASH Presentations May Help Clear Cloudy Outlook
-
Sage (SAGE) SRSE Data is Positive for Ligand Pharma (LGND) - Roth
-
Roth Capital Downgrades Planar Systems (PLNR) to Neutral
-
Roth Capital Upgrades ICU Medical (ICUI) to Buy
-
Roth Affirms Curis (CRIS) at 'Buy' Following Q3 Report, Update; Pipeline Progress is Encouraging
-
Streetinsider.com's Hot Lunchtime Reads 11/10: (TWTR) (HIMX) (SVU) (AGU)
-
Roth Capital 'Encouraged' by PoC Data from Celldex's (CLDX) Varlilumab Phase 1

